Risk assessment in haematopoietic stem cell transplantation: The liver as a risk factor

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 2, 2007, Pages 231-246

  Carreras, Enric ^a  

^a ICMHO   (Spain)

Author keywords

early and late complications of transplantation; haematopoietic stem cell transplantation; HBV and HCV infection; patient management in HSCT; prevention of hepatic complications

Indexed keywords

ALCOHOL; ALLOPURINOL; AMIODARONE; AMOXICILLIN; AMPHETAMINE; ANABOLIC AGENT; ARSENIC; CARBAMAZEPINE; CIPROFLOXACIN; COCAINE; CONTRACEPTIVE AGENT; DAPSONE; DICLOFENAC; ERYTHROMYCIN; HEPATITIS B VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INTERFERON; ISONIAZID; LAMIVUDINE; METHOTREXATE; METHYLDOPA; NIFEDIPINE; PARACETAMOL; PHENYTOIN; PYRROLE DERIVATIVE; RIBAVIRIN; RIFAMPICIN; STEROID; UNINDEXED DRUG;

ALCOHOLISM; ANAMNESIS; COMPUTER ASSISTED TOMOGRAPHY; DONOR; DONOR SELECTION; DRUG USE; ECHOGRAPHY; FAMILY HISTORY; GALLBLADDER DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER VENOOCCLUSIVE DISEASE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SEXUAL DYSFUNCTION;

ANTIVIRAL AGENTS; BIOPSY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS C; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER FUNCTION TESTS; PHYSICAL EXAMINATION; RISK ASSESSMENT;

EID: 34247148457     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.10.010     Document Type: Review

References (72)

1. Blume K.G., and Amylon M.D. The evaluation and counselling of candidates for hematopoietic cell transplantation. In: Blume K.G., Forman S.J., and Appelbaum F. (Eds). Thomas' Hematopoietic Cell Transplantation (2004), Blackwell Sciences, Malden, MA 449-462
2. Confer D.L. Hematopoietic cell donor. In: Blume K.G., Forman S.J., and Appelbaum F. (Eds). Thomas' Hematopoietic Cell Transplantation (2004), Blackwell Sciences, Malden, MA 538-549
3. Strasser S.I., and McDonald G.B. Gastrointestinal and hepatic complications. In: Blume K.G., Forman S.J., and Appelbaum F. (Eds). Thomas' Hematopoietic Cell Transplantation (2004), Blackwell Sciences, Malden, MA 769-809
4. Carreras E., Bertz H., Arcese W., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92 (1998) 3599-3604
5. Socie G., Salooja N., Cohen A., et al. Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation. Non-malignant late effects after allogeneic stem cell transplantation. Blood 101 (2003) 3373-3385
6. Angelucci E., Muretto P., Nicolucci A., et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100 (2002) 17-21
7. Peffault de Latour R., Levy V., Asselah T., et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103 (2004) 1618-1624
8. Gratwohl A., Speck B., Wenk M., et al. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity. Transplantation 36 (1983) 40-44
9. McIntyre N. Symptoms and signs of liver disease. In: Bircher J., Benhamou J.P., McIntyre N., Rizzetto M., and Rodés J. (Eds). Oxford Textbook of Clinical Hepatology. 2nd edn. (1999), Oxford University Press, Oxford 479-499
10. Van deursen C., Delaere K., and Tenkate J. Hemochromatosis and sexual dysfunction. International Journal of Impotence Research 15 (2003) 430-432
11. Prieto J.M., Saez R., Carreras E., et al. Physical and psychosocial functioning of 117 survivors of bone marrow transplantation. Bone Marrow Transplantation 17 (1996) 1133-1142
12. Rosalki S.B., and McIntyre N. Biochemical investigations in the management of liver disease. In: Bircher J., Benhamou J.P., McIntyre N., Rizzetto M., and Rodés J. (Eds). Oxford Textbook of Clinical Hepatology. 2nd edn. (1999), Oxford University Press, Oxford 503-521
13. Gordon L.I., Brown S.G., Tallman M.S., et al. Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity. Free Radical Biology & Medicine 18 (1995) 383-389
14. Foerder C.A., Tobin A.A., McDonald G.B., et al. Bleomycin-detectable iron in plasma of bone-marrow transplant patients -its correlation to liver injury. Transplantation 54 (1992) 1120-1123
15. Muretto P., Del Fiasco S., Angelucci E., et al. Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting. Liver 14 (1994) 14-24
16. Lucarelli G., Galimberti M., Polchi P., et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. The New England Journal of Medicine 329 (1993) 840-844
17. Bonkovsky H.L., Banner B.F., and Rothman A.L. Iron and chronic viral hepatitis. Hepatology 25 (1997) 759-768
18. Strasser S.I., Kowdley K.V., Sale G.E., et al. Iron overload in bone marrow transplant recipients. Bone Marrow Transplantation 22 (1998) 167-173
19. Maertens J., Demuynck H., Verbeken E.K., et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplantation 24 (1999) 307-312
20. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107 (2006) 3436-3441
21. Tibballs J., Watkinson A.F., and Menu Y. Imaging of the liver and biliary tract. In: Bircher J., Benhamou J.P., McIntyre N., Rizzetto M., and Rodés J. (Eds). Oxford Textbook of Clinical Hepatology. 2nd edn (1999), Oxford University Press, Oxford 549-578
22. Kawamoto M., Mizuguchi T., Katsuramaki T., et al. Assessment of liver fibrosis by a non-invasive method of transient elastography and biochemical markers. World Journal of Gastroenterology 12 (2006) 4325-4330
23. Verveer C., and De Knegt R.J. Non-invasive measurement of liver fibrosis: Application of the FibroScan(R) in hepatology. Scandinavian Journal of Gastroenterology. Supplement 243 (2006) 85-88
24. Strasser S.I., and McDonald G.B. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood 93 (1999) 1127-1136
25. Carreras E., Grañena A., Navasa M., et al. Transjugular liver biopsy in BMT. Bone Marrow Transplantation 11 (1993) 21-26
26. Dodd R.Y. Current safety of the blood supply in the United States. International Journal of Hematology 80 (2004) 301-305
27. Locasciulli A., Alberti A., de Bock R., et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group-Infectious Diseases Working Party. Bone Marrow Transplantation 14 (1994) 833-837
28. Idilman R., Ustun C., Karayalcin S., et al. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clinical Transplantation 17 (2003) 438-443
29. Yim H.J., and Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43 supplement 1 (2006) S173-S181
30. Rovira R., and Carreras E. Otras infecciones víricas. In: Carreras E. (Ed). Manual de Trasplante Hematopoyético. 3rd edn. (2004), Editorial Antares, Barcelona 401-408
31. + donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 86 (1995) 3236-3240
32. Locasciulli A., Bacigalupo A., Van Lint M.T., et al. Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases. Bone Marrow Transplantation 6 (1990) 25-29
33. Lau G.K., Liang R., Chiu E.K., et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplantation 19 (1997) 795-799
34. Locasciulli A., Bruno B., Alessandrino E.P., et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplantation 31 (2003) 295-300
35. Lau G.K., Lie A.K., Kwong Y.L., et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 96 (2000) 452-458
36. Chan P.C., Chen H.L., Kong M.S., et al. Factors affecting the mortality of pediatric fulminant hepatic failure in relation to hepatitis B virus infection. Journal of Gastroenterology and Hepatology 20 (2005) 1223-1227
37. Hsiao L.T., Chiou T.J., Liu J.H., et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biology of Blood and Marrow Transplantation 12 (2006) 84-94
38. Hui C.K., Lie A., Au W.Y., et al. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. American Journal of Transplantation 5 (2005) 1437-1445
39. Lin P.C., Poh S.B., Lee M.Y., et al. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. International Journal of Hematology 81 (2005) 349-351
40. McIvor C., Morton J., Bryant A., et al. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Annals of Internal Medicine 121 (1994) 274-275
41. Tedder R.S., Zuckerman M.A., Goldstone A.H., et al. Hepatitis B transmission from contaminated cryopreservation tank. Lancet 346 (1995) 137-140
42. Dhedin N., Douvin C., Kuentz M., et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 66 (1998) 616-619
43. Onozawa M., Hashino S., Izumiyama K., et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79 (2005) 616-619
44. Ljungman P., Engelhard D., de la Camara R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplantation 35 (2005) 737-746
45. Locasciulli A., and Alberti A. Hepatitis C virus serum markers and liver disease in children with leukemia. Leukemia & Lymphoma 17 (1995) 245-249
46. Strasser S.I., Myerson D., Spurgeon C.L., et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 29 (1999) 1893-1899
47. Frickhofen N., Wiesneth M., Jainta C., et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 83 (1994) 1998-2004
48. Ljungman P., Hagglund H., Lonnqvist B., et al. Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver. Blood 84 (1994) 1349-1350
49. Norol F., Roche B., Girardin M.F., et al. Hepatitis C virus infection and allogeneic bone marrow transplantation. Transplantation 57 (1994) 393-397
50. Locasciulli A., Bacigalupo A., VanLint M.T., et al. Hepatitis C virus infection and liver failure in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 16 (1995) 407-411
51. Fujii Y., Kaku K., Tanaka M., et al. Hepatitis C virus infection and liver disease after allogeneic bone marrow transplantation. Bone Marrow Transplantation 13 (1994) 523-526
52. Maruta A., Kanamori H., Fukawa H., et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplantation 13 (1994) 417-422
53. Ljungman P., Johansson N., Aschan J., et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 86 (1995) 1614-1618
54. Shulman H.M., Sharma P., Amos D., et al. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 8 (1988) 463-470
55. Kaji K., Nakanuma Y., Sasaki M., et al. Hepatitic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies. Modern Pathology 7 (1994) 937-945
56. Goodman Z.D., and Ishak K.G. Histopathology of hepatitis C virus infection. Seminars in Liver Disease 15 (1995) 70-81
57. Strasser S.I., Sullivan K.M., Myerson D., et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 93 (1999) 3259-3266
58. Ribas A., and Gale R.P. Should people with hepatitis C virus infection receive a bone marrow transplant?. Bone Marrow Transplantation 19 (1997) 97-99
59. Ljungman P., Andersson J., Aschan J., et al. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clinical Infectious Diseases 23 (1996) 167-169
60. Dusheiko G., Main J., Thomas H., et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Journal of Hepatology 25 (1996) 591-598
61. Di Bisceglie A.M., Conjeevaram H.S., Fried M.W., et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 123 (1995) 897-903
62. Carlsson T., Reichard O., Norkrans G., et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. Journal of Viral Hepatitis 12 (2005) 473-480
63. Ferenci P., Formann E., Laferl H., et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. Journal of Hepatology 44 (2006) 275-282
64. de Latour R.P., Asselah T., Levy V., et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation 36 (2005) 709-713
65. Chen P.M., Liu J.H., Fan F.S., et al. Liver disease after bone marrow transplantation-the Taiwan experience. Transplantation 59 (1995) 1139-1143
66. Ustun C., Koc H., Karayalcin S., et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplantation 20 (1997) 289-296
67. Main J., Brown J.L., Howells C., et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis 3 (1996) 211-215
68. Yao G., Wang B., Cui Z., et al. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chinese Medical Journal 112 (1999) 387-391
69. Chiba T., Yokosuka O., Goto S., et al. Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine. European Journal of Haematology 71 (2003) 220-223
70. Mason A.L., Xu L., Guo L., et al. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 27 (1998) 1736-1742
71. Lau G.K., Liang R., Lee C.K., et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. The Journal of Infectious Diseases 178 (1998) 1585-1591
72. Shuhart M.C., Myerson D., Childs B.H., et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood 84 (1994) 3229-3235